Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

postmenopausal osteoporosis

- PMLiVE

Dr. Reddy’s enters €118m product agreement with UCB in India

Portfolio acquisition will expand firm’s therapy footprint

- PMLiVE

Amgen gets EU nod for wider use of Vectibix

US biotech’s cancer therapy can now be used in a first-line setting

- PMLiVE

Amgen gets quick US review for Kyprolis

To be considered as a second-line therapy for multiple myeloma

- PMLiVE

UCB and MRC join forces on novel antibody discovery platform

Will provide UK scientists with access to up-to-date technologies

- PMLiVE

Icelandic genome study yields new disease genes

Nature Medicine study focuses on the probability of developing Alzheimer’s

- PMLiVE

UCB: Patient centricity should move a business forward

Pharma may become obsolete if it does not include the patient voice, says Lode Dewulf

- PMLiVE

UCB plans epilepsy ‘hackathon’ to develop new digital tools

Aims to attract developers, designers and digital experts to Hack Epilepsy

- PMLiVE

FDA approves first biosimilar

Novartis’ Sandoz unit gains new licence for Neupogen copycat

- PMLiVE

Amgen’s Kyprolis tops Velcade in myeloma trial

Amgen hoping to topple Takeda’s $2bn a year drug

- PMLiVE

UCB boosted by core medicines growth

Firm’s new chief executive 'excited' by his company’s next batch of medicines

National Institute for Health and Care Excellence NICE logo

NICE backs biosimilars in rheumatoid arthritis guidance

Seven biologic drugs (DMARDs) and two biosimilars recommended

UCB CEO elected to the Ministerial Industry Strategy Group

Jean-Christophe Tellier assumed the role of CEO on January 1

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links